Loading
Every dated change on the records linked to Gastrointestinal stromal tumour (GIST), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Unresectable/metastatic GIST with PDGFRA exon 18 mutation including D842V
Advanced GIST after ≥3 prior kinase inhibitors including imatinib
Very high, durable response rate in PDGFRA D842V-mutant GIST; approved for that indication in January 2020.
A milestone in how this cancer is treated.
GIST after imatinib and sunitinib
Regorafenib lengthened progression-free survival compared with placebo in GIST after imatinib and sunitinib; approved in February 2013.
A milestone in how this cancer is treated.